Rising Demand for Psychological Support Among Children with Food Allergies
A recent study reveals a 50% increase in psychological referrals for children with food allergies from 2018 to 2023, highlighting the growing need for mental health support. Conducted by Nationwide Children’s Hospital, the research underscores the anxiety related to food allergies and the importance of addressing both physical and psychological aspects of care. With over half of the children experiencing anaphylaxis, healthcare providers are urged to integrate mental health services into treatment plans.
Understanding and Managing Seasonal Allergies in Dogs
Learn how seasonal allergies can affect dogs, common allergens, signs to watch for, breeds prone to allergies, and effective treatment options to help your furry friend find relief and live a healthy life.
Trial Shows Remarkable Improvements in Children with Peanut Allergies
Children with peanut and milk allergies are seeing significant improvements through a new trial funded by the Natasha Allergy Research Foundation. The trial involves using everyday foods to gradually increase patients’ tolerance to allergens, with participants like 11-year-old Thomas and five-year-old Grace experiencing life-changing results. The foundation, established in memory of Natasha Ednan-Laperouse, aims to find cures for allergies and advocate for food law changes.
Researchers Discover Early Indicators of Childhood Food Allergies
Researchers at National Jewish Health have discovered early indicators of food allergies in babies as young as two months old through a noninvasive skin tape sampling method. The study, published in the Journal of Allergy & Clinical Immunology, aims to identify people at risk for food allergy and address skin barrier abnormalities early to prevent the development of these conditions.
FDA Approves Omalizumab for Reduction of Allergic Reactions in Patients with Food Allergies
FDA approves omalizumab (Xolair; Novartis) as the first and only medicine to reduce allergic reactions in patients with food allergies. The drug is not for emergency treatment and patients should continue avoiding allergenic foods. Positive results from the phase 3 OUtMATCH study show potential for omalizumab to mitigate allergic reactions in patients with multiple food allergies.